Abstract
Background: Breast cancer is the leading cause of cancer in women. 13% of breast cancer
patients are at a distant stage and mortality is due to metastases rather than primary disease.
The unique genetic structure and natural process of breast cancer make it a very suitable area for
targeted therapies. Experimental tumor models are validated methods to examine the pathogenesis
of cancer, the onset of the neoplastic process and progression.
Objective: This study aims to review the current literature on experimental breast cancer models
and to bring a new perspective to the use of these models in teranostic preclinical studies in terms
of the imaging.
Methods: Search for relevant literature from academic databases using keywords (Breast cancer,
theranostic, preclinical imaging, tumor models, animal study, and tailored therapy) was conducted.
The full text of the articles was reached and reviewed. Current scientific data has been reevaluated
and compiled according to subtitles.
Results and Conclusion: The development of animal models for breast cancer research has been
done in the last century. Imaging methods used in breast cancer are used for tumor localization,
quantification of tumor mass, imaging of genes and proteins, evaluation of tumor microenvironment,
evaluation of tumor cell proliferation and metabolism and treatment response evaluation.
Since human breast cancer is a heterogeneous group of diseases in terms of genetics and phenotype;
it is not possible for a single model to adequately address all aspects of breast cancer biology.
Considering that each model has advantages and disadvantages, the most suitable model should be
chosen to verify the thesis of the study.
Keywords:
Breast cancer, theranostic, preclinical imaging, tumor models, animal study, tailored therapy.
Graphical Abstract
[12]
Rudolph, M; Sizemore, S.T; Lu, Y; Teng, K.Y; Basree, M.M; Reinbolt, R. A hedgehog pathway‑dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer. Breast Cancer Research and Treatment,, 2018, 169, 457-67.
[21]
Bhatnagar, S; Dhingra Verma, K; Hu, Y; Khera, E; Priluc, A; David, E; Smith, D.E. Oral Administration and Detection of a Near-Infrared Molecular Imaging Agent in an Orthotopic Mouse Model for Breast Cancer Screening. Mol. Pharmaceutics,, 2018, 15, 1746-1754.
[25]
Doganlar, O.; Doganlar, Z.B. Optik Görüntüleme in Deney hayvanlarında moleküler görüntüleme. G. Durmus-Altun and F.Ustun; Kitabevleri, N.T., Ed.; İstanbul, 2015, pp. 123-140.
[26]
Torun, N. Radionüklid Tedavi in Deney hayvanlarında moleküler görüntüleme. G. Durmus-Altun and F.Ustun; Kitabevleri, N.T., Ed.; İstanbul, 2015, pp. 241-246.
[27]
Unak, P. Radiofarmasi ve Biyodagılım Deney hayvanlarında moleküler görüntüleme. G. Durmus-Altun and F.Ustun; Kitabevleri, N.T., Ed.; İstanbul, 2015, pp. 96-105.
[28]
Soyluoglu Demir, S. Görüntüleme Protokolleri in Deney hayvanlarında moleküler görüntüleme. G. Durmus-Altun and F.Ustun; Kitabevleri, N.T., Ed.; İstanbul, 2015, pp. 251-262.
[29]
Karacalıoglu, A.O. Otoradiografi Deney hayvanlarında moleküler görüntüleme. G. Durmus-Altun and F.Ustun; Kitabevleri, N.T., Ed.; İstanbul, 2015, pp. 109-120.
[30]
Kula, M. Deney hayvanlarında SPECT: Temel Prensipler ve Protokoller Deney hayvanlarında moleküler görüntüleme. G. Durmus-Altun and F.Ustun; Kitabevleri, N.T., Ed.; İstanbul, 2015, pp. 195-205.
[32]
Parkins, K.M; Dubois, V.P; Hamilton, A.M; Makela, A.V Multimodality cellular and molecular imaging of concomitant tumour enhancement in a syngeneic mouse model of breast cancer metastasis. Scientific Reports, 2018, 8, 8930.
[33]
Korkmaz, U.; Aras, O. Prostat kanseri tanı ve cerrahisinde NIR floresans görüntüleme ajanlarının F-18 PSMA ile konjugasyonunun getirileri. Prostat Kanseri Olgularında Yeni Nükleer Tıp Görüntüleme Yöntemleri. Sayman, H.B; Klinikleri, T., Ed.; Ankara, 2019, pp. 44-48.